Therapy Areas: Diabetes
Novo Nordisk agrees to pay USD58.65m to settle Victoza charges
8 September 2017 -

It was reported yesterday that Denmark-based Novo Nordisk has agreed to pay USD58.65m to settle charges over the marketing of its type 2 diabetes drug Victoza (liraglutide) in the United States.

The settlement with the US federal government covers claims the company didn't comply with the USFDA's Risk Evaluation and Mitigation Strategy for the diabetes medication. An investigation into the charges was started in February 2011 regarding the sales and marketing practices of the Novo Nordisk diabetes drug.

Novo Nordisk will compensate around USD46.5m to the US government and to states that reimbursed for the medication under the Medicaid programme, along with USD12.15m to resolve a complaint filed by the government on FDA's behalf.

Login
Username:

Password: